As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
Featured article: Proximal deep vein thrombosis and pulmonary embolism in COVID-19 patients: a systematic review and meta-analysis
COVID-19 appears to be associated with a high risk of venous thromboembolism (VTE). We aimed to systematically review and meta-analyze the risk of clinically relevant VTE in patients hospitalized for COVID-19.
Articles
-
-
An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention
-
Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article
-
Prevalence, risk, and outcome of deep vein thrombosis in acute respiratory distress syndrome
-
Use of laboratory testing for prediction of postoperative bleeding volume in cardiovascular surgery
-
Heparin-induced thrombocytopenia: an update
-
Laboratory assessment of rivaroxaban: a review
-
Practical management of patients on apixaban: a consensus guide
-
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
-
Hereditary thrombophilia
Recommended reading
Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis
Kochawan Boonyawat, Pichika Chantrathammachart, Pawin Numthavaj, Nithita Nanthatanti, Sithakom Phusanti, Angsana Phuphuakrat, Pimjai Niparuck & Pantep Angchaisuksiri
Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia
Xueya Zhang & Xizhe Guo
Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer
Nadia I Abelhad, Wei Qiao, Naveen Garg &
Cristhiam M. Rojas-Hernandez
Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort
Mark M. G. Mulder, LIoyd Brandts, Renée A. G. Brüggemann, Marcel Koelmann, Alexander S. Streng, Renske H. Olie, Hester A. Gietema, Henri M. H. Spronk, Iwan C. C. van der Horst, Jan-Willem E. M. Sels, Joachim E. Wildberger, Sander M. J. van Kuijk, Ronny M. Schnabel, Hugo ten Cate, Yvonne M. C. Henskens & Bas C. T. van Bussel
Trending articles
Click here to view the most shared articles in the last month!
Aims and scope
Thrombosis Journal is an open-access journal that publishes original articles on aspects of clinical and basic research, new methodology, case reports and reviews in the areas of thrombosis.
Topics of particular interest include the diagnosis of arterial and venous thrombosis, new antithrombotic treatments, new developments in the understanding, diagnosis and treatments of atherosclerotic vessel disease, relations between haemostasis and vascular disease, hypertension, diabetes, immunology and obesity.
Asian-Pacific Society on Thrombosis and Hemostasis
The Asian-Pacific Society of Thrombosis and Hemostasis (APSTH) is a non-profit organization that welcomes any medical or scientific professionals with an interest in the field of thrombosis and hemostasis, particularly those professionals from the Asia Pacific Region.
The main objectives of APSTH are to foster and advance clinical and scientific knowledge in the field of thrombosis, hemostasis and vascular biology through promotion of scientific exchange via meetings, publications, and promotion of international cooperation in clinical studies, and standardization of nomenclature and practices in the Asia-Pacific region.
Editors' quotes
“It is with great pleasure that I join the Editorial team of Thrombosis Journal and to take on the role as co-Editor-in-Chief (EiC). This is indeed a great honor for me. For your information, I am a biochemist and have been active in the field of Thrombosis and Haemostasis with a particular interest in fibrinolysis for over 38 years. I am looking forward to making a positive contribution to Thrombosis Journal. I would very much like to thank and acknowledge the many years at the helm by my predecessor Prof Hugo Ten Cate. I will do my best to fill Hugo’s shoes. I would also like to acknowledge the long-lasting role of Yukio Ozaki as co-EiC who will be continuing in this role. I am looking forward to working with Prof Ozaki and the dedicated Associate Editors to develop and implement new ideas and approaches to improve the standing of the Journal.”
Robert Medcalf, Editor-in-Chief, Thrombosis Journal
"Treatment and prophylaxis of thrombotic and bleeding disorders is of great importance to the worldwide population, and there is a great need to facilitate the research activities related to this field. The aim of Thrombosis Journal is to provide a platform on which these important studies are visible to all members of the scientific community and public."
Yukio Ozaki, Editor-in-Chief, Thrombosis Journal
Official journal of
-
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Follow
Annual Journal Metrics
-
Speed
55 days to first decision for reviewed manuscripts only
42 days to first decision for all manuscripts
80 days from submission to acceptance
13 days from acceptance to publication
Citation Impact
5.500 2-Year-Impact-Factor
4.416 5-Year-Impact-Factor - Impact Factor
1.126 - Source Normalized Impact per Paper (SNIP)
1.004 - SCImago Journal Rank (SJR)
Usage
395,336 Downloads
259 Altmetric mentions